Global Pharmacogenomics Market

Focus on Services, Applications, Technologies, End Users, Country Data (16 Countries), and Competitive Landscape – Analysis and Forecast, 2019-2028

Published Year: 2019
SKU: BH00366SB

5000

Online Access for 1-3 Users. Permission to Print.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Table of Contents

Download this TOC  

Request a Sample

1 Market Overview

         1.1    Introduction
         1.2    Market Definition
         1.3    Historical Perspective
         1.4    Significant Services in Pharmacogenomics
         1.5    Classification of Pharmacogenomics
         1.6    Global Footprint
         1.7    Future Potential

2 Market Dynamics

          2.1    Overview
          2.2    Iceberg Analysis - Global Pharmacogenomics Market
          2.3    Impact Analysis
          2.4    Market Drivers
                   2.4.1    Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
                   2.4.2    Increase in Adoption of Personalized Medicine Shifting the Paradigm From Reaction to Prevention on a Global Level
                   2.4.3    Increasing Rate of Adverse Drug Reaction
                   2.4.4    Surge in Usage of Pharmacogenomics for Drug Discovery and Development
          2.5    Market Restraints
                   2.5.1    Lack of Use of Available Data for Drug Development Initiatives
                   2.5.2    Lack of High Complexity Testing Centers
                   2.5.3    Difficulties in Detecting Gene Variation Affecting Drug Response
          2.6    Market Opportunities
                   2.6.1    Massive Scope for Adoption of Pharmacogenomics in Emerging Nations
                   2.6.2    Technological Advancements in Molecular Techniques for Pharmacogenomic Diagnostic Tests
                   2.6.3    Rise of Direct-to-Consumer (DTC) Testing Services

3 Competitive Landscape

          3.1    Key Strategies and Developments
                   3.1.1    Product Launches and Enhancements
                   3.1.2    Product Approvals
                   3.1.3    Synergistic Activities
                   3.1.4    Mergers and Acquisitions
                   3.1.5    Business Expansion Activities and Others
          3.2    Market Share Analysis
          3.3    Growth Share Analysis
          3.4    Industry Attractiveness
                   3.4.1    Bargaining Power of Suppliers
                   3.4.2    Bargaining Power of Buyers
                   3.4.3    Threat of New Entrants
                   3.4.4    Threat of Substitute Products
                   3.4.5    Intensity of Competitive Rivalry

4 Regulatory Framework

          4.1    Legal Requirements and Framework in the U.S.
          4.2    Legal Requirements and Framework in Europe
          4.3    Legal Requirements and Framework in Asia-Pacific
                   4.3.1    China
                   4.3.2    Japan
          4.4    Patent Landscape

5 Global Pharmacogenomics Market (by Service)

          5.1    Overview
          5.2    Genotyping
          5.3    SNP Identification
          5.4    Pharmacogenetic Testing
          5.5    Other Services

6 Global Pharmacogenomics Market (by Application)

          6.1    Overview
          6.2    Oncology
          6.3    Infectious Diseases
          6.4    Neurology/Psychiatry
          6.5    Cardiovascular
          6.6    Other Applications

7 Global Pharmacogenomics Market (by Technology)

          7.1    Overview
          7.2    Polymerase Chain Reaction (PCR)
          7.3    Microarray
          7.4    Sequencing
          7.5    Other Technologies

8 Global Pharmacogenomics Market (by End User)

          8.1    Overview
          8.2    Research Organizations
                   8.2.1    Research Organizations (by Service)
          8.3    Pharmaceutical Companies
                   8.3.1    Pharmaceutical Companies (by Service)
          8.4    Diagnostic Centers
                   8.4.1    Diagnostics Centers (by Service)
          8.5    Other End Users

9 Global Pharmacogenomics Market (by Region)

          9.1    Overview
          9.2    North America
                   9.2.1    The U.S.
                   9.2.2    Canada
                   9.2.3    North America Pharmacogenomics Market (by Application)
                   9.2.4    North America Pharmacogenomics Market (by Service)
          9.3    Europe
                   9.3.1    Germany
                   9.3.2    The U.K.
                   9.3.3    France
                   9.3.4    Italy
                   9.3.5    Spain
                   9.3.6    Denmark
                   9.3.7    The Netherlands
                   9.3.8    Rest-of-Europe
                   9.3.9    Europe Pharmacogenomics Market (by Application)
                   9.3.10    Europe Pharmacogenomics Market (by Service)
          9.4    Asia-Pacific
                   9.4.1    Japan
                   9.4.2    China
                   9.4.3    Australia
                   9.4.4    India
                   9.4.5    Singapore
                   9.4.6    Rest-of-APAC
                   9.4.7    Asia-Pacific Pharmacogenomics Market (by Application)
                   9.4.8    Asia-Pacific Pharmacogenomics Market (by Service)
          9.5    Latin America
                   9.5.1    Brazil
                   9.5.2    Mexico
                   9.5.3    Rest-of-Latin America
                   9.5.4    Latin America Pharmacogenomics Market (by Application)
                   9.5.5    Latin America Pharmacogenomics Market (by Service)
          9.6    Rest-of-the-World
                   9.6.1    RoW Pharmacogenomics Market (by Application)
                   9.6.2    RoW Pharmacogenomics Market (by Service)

10 Company Profiles

            10.1    Overview
            10.2    Abbott Laboratories
                       10.2.1    Company Overview
                       10.2.2    Role of Abbott Laboratories in the Global Pharmacogenomics Market
                       10.2.3    Financials
                       10.2.4    Key Insights about Financial Health of the Company
                       10.2.5    SWOT Analysis
            10.3    Admera Health, LLC
                       10.3.1    Company Overview
                       10.3.2    Role of Admera Health, LLC in the Global Pharmacogenomics Market
                       10.3.3    SWOT Analysis
            10.4    Agena Biosciences, Inc.
                       10.4.1    Company Overview
                       10.4.2    Role of Agena Biosciences, Inc. in the Global Pharmacogenomics Market
                       10.4.3    SWOT Analysis
            10.5    Cancer Genetics, Inc.
                       10.5.1    Company Overview
                       10.5.2    Role of Cancer Genetics, Inc. in the Global Pharmacogenomics Market
                       10.5.3    Financials
                       10.5.4    Key Insights about Financial Health of the Company
                       10.5.5    SWOT Analysis
            10.6    Dynamic DNA Laboratories
                       10.6.1    Company Overview
                       10.6.2    Role of Dynamic DNA Laboratories in the Global Pharmacogenomics Market
                       10.6.3    SWOT Analysis
            10.7    F. Hoffmann-La Roche Ltd
                       10.7.1    Company Overview
                       10.7.2    Role of F. Hoffmann-La Roche Ltd in the Global Pharmacogenomics Market
                       10.7.3    Financials
                       10.7.4    Key Insights about Financial Health of the Company
                       10.7.5    SWOT Analysis
            10.8    geneOmbio Technologies Pvt Ltd.
                       10.8.1    Company Overview
                       10.8.2    Role of geneOmbio Technologies Pvt Ltd. in the Global Pharmacogenomics Market
                       10.8.3    SWOT Analysis
            10.9    Genomic Health, Inc.
                       10.9.1    Company Overview
                       10.9.2    Role of Genomic Health, Inc. in the Global Pharmacogenomics Market
                       10.9.3    Financials
                       10.9.4    Key Insights about Financial Health of the Company
                       10.9.5    SWOT Analysis
           10.10   Illumina, Inc.
                       10.10.1    Company Overview
                       10.10.2    Role of Illumina, Inc. in the Global Pharmacogenomics Market
                       10.10.3    Financials
                       10.10.4    Key Insights about Financial Health of the Company
                       10.10.5    SWOT Analysis
            10.11   Laboratory Corporation of America Holdings
                       10.11.1    Company Overview
                       10.11.2    Role of Laboratory Corporation of America Holdings in the Global Pharmacogenomics Market
                       10.11.3    Financials
                       10.11.4    SWOT Analysis
           10.12   Myriad Genetics, Inc.
                       10.12.1    Company Overview
                       10.12.2    Role of Myriad Genetics, Inc. in the Global Pharmacogenomics Market
                       10.12.3    Financials
                       10.12.4    SWOT Analysis
           10.13   Pathway Genomics Corporation
                       10.13.1    Company Overview
                       10.13.2    Role of Pathway Genomics Corporation in the Global Pharmacogenomics Market
                       10.13.3    SWOT Analysis
           10.14   QIAGEN N.V.
                       10.14.1    Company Overview
                       10.14.2    Role of QIAGEN N.V. in the Global Pharmacogenomics Market
                       10.14.3    Financials
                       10.14.4    Key Insights about Financial Health of the Company
                       10.14.5    SWOT Analysis
           10.15   Quest Diagnostics Incorporated
                       10.15.1    Company Overview
                       10.15.2    Role of Quest Diagnostics Incorporated in the Global   Pharmacogenomics Market
                       10.15.3    Financials
                       10.15.4    SWOT Analysis
           10.16   Thermo Fisher Scientific Inc.
                       10.16.1    Company Overview
                       10.16.2    Role of Thermo Fisher Scientific Inc. in the Global Pharmacogenomics Market
                       10.16.3    Financials
                       10.16.4    Key Insights about Financial Health of the Company
                       10.16.5    SWOT Analysis
           10.17   Transgenomic, Inc.
                       10.17.1    Company Overview
                       10.17.2    Role of Transgenomic, Inc. in the Global Pharmacogenomics Market
                       10.17.3    SWOT Analysis
           10.18   23andMe, Inc.
                       10.18.1    Company Overview
                       10.18.2    Role of 23andMe, Inc. in the Global Pharmacogenomics Market
           10.19   OneOme, LLC
                       10.19.1    Company Overview
                       10.19.2    Role of OneOme, LLC in the Global Pharmacogenomics Market
           10.20   Astra Zeneca PLC
                       10.20.1    Company Overview
                       10.20.2    Role of Astra Zeneca PLC in the Global Pharmacogenomics Market

11 Research Scope and Methodology

            11.1    Research Scope
            11.2    Global Pharmacogenomics Market: Research Methodology

List of Tables

Table 2.1:    Impact Analysis of Market Drivers
Table 2.2:    Impact Analysis of Market Restraints
Table 2.3:    Examples of Adverse Drug Reactions
Table 4.1:    Classification rules of IVDs under the IVDR
Table 4.2:    Registration Criteria for IVD Medical Devices as per the CFDA

List of Figures

Figure 1:    Estimates for Global Healthcare Market, 2018 and 2020
Figure 2:    Impact of Market Drivers and Market Restraints on the Global Pharmacogenomics Market
Figure 3:    Global Pharmacogenomics Market Snapshot (in $Million)
Figure 4:    Dominating Segments of the Global Pharmacogenomics Market, 2018 and 2028
Figure 5:    Global Pharmacogenomics Market (by Service), 2018 and 2028
Figure 6:    Global Pharmacogenomics Market (by Application), 2018 and 2028
Figure 7:    Global Pharmacogenomics Market (by Technology), 2018 and 2028
Figure 8:    Global Pharmacogenomics Market (by End User), 2018 and 2028
Figure 9:    Global Pharmacogenomics Market (by Region), 2018 and 2028
Figure 1.1:    Evolution of Pharmacogenomics
Figure 1.2:    Classification of Pharmacogenomics
Figure 1.3:    Global Pharmacogenomics (PGx) Market, 2018-2028
Figure 2.1:    Iceberg Analysis - Global Pharmacogenomics Market
Figure 2.2:    Number of Deaths by Top 18 Infectious Diseases, 2015
Figure 2.3:    Number of Deaths (in Millions) by Different Forms of Cancer, 2018
Figure 2.4:    Benefits of Multiplexing Reactions
Figure 3.1:    Share of Key Developments and Strategies, January 2016 – April 2019
Figure 3.2:    Product Launches Share (by Company), January 2016 – April 2019
Figure 3.3:    Product Approvals Share (by Company), January 2016 – April 2019
Figure 3 4:    Synergistic Activities Share (by Company), January 2016 – April 2019
Figure 3.5:    Market Share Analysis for the Global Pharmacogenomics Market, 2017
Figure 3.6:    Market Share Analysis for the Global Pharmacogenomics Market, 2018
Figure 3.7:    Growth Share Matrix for Global Pharmacogenomics Market (by Companies), 2018
Figure 3.8:    Overall Industry Attractiveness, 2018 and 2028
Figure 3.9:    Overall Impact of Bargaining Power of Suppliers
Figure 3.10:    Overall Impact of Bargaining Power of Buyers
Figure 3.11:    Overall Impact of Threat of New Entrants
Figure 3.12:    Overall Impact of Threat of Substitute Products
Figure 3.13:    Overall Impact of Intensity of Competitive Rivalry
Figure 4.1:    Components Considered for Clinical Evidence as per the IVDR
Figure 4.2:    Process of Medical Device Designation by the MHLW and PMDA
Figure 4.3:    Share of Patents (by Ownership), 2016-2019
Figure 5.1:    Global Pharmacogenomics Market (by Service)
Figure 5.2:    Global Pharmacogenomics Market (by Service), 2018 and 2028
Figure 5.3:    Global Pharmacogenomics Market (by Genotyping Service), 2018-2028
Figure 5.4:    Global Pharmacogenomics Market (by SNP Identification Service), 2018-2028
Figure 5.5:    Global Pharmacogenomics Market (by Pharmacogenetic Testing Service), 2018-2028
Figure 5.6:    Global Pharmacogenomics Market (by Other Testing Services), 2018-2028
Figure 6.1:    Global Pharmacogenomics Market (by Application)
Figure 6.2:    Global Pharmacogenomics Market (by Application), 2018 and 2028
Figure 6.3:    Global Pharmacogenomics Market (by Oncology), 2018-2028
Figure 6.4:    Global Pharmacogenomics Market (by Infectious Diseases), 2018-2028
Figure 6.5:    Global Pharmacogenomics Market (by Neurology/Psychiatry), 2018-2028
Figure 6.6:    Global Pharmacogenomics Market (by Cardiovascular), 2018-2028
Figure 6.7:    Global Pharmacogenomics Market (by Other Applications), 2018-2028
Figure 7.1:    Global Pharmacogenomics Market (by Technology)
Figure 7.2:    Global Pharmacogenomics Market (by Technology), 2018 and 2028
Figure 7.3:    Global Pharmacogenomics Market (by PCR), 2018-2028
Figure 7.4:    Global Pharmacogenomics Market (by Microarray), 2018-2028
Figure 7.5:    Evolution of Sequencing for Molecular Diagnostics
Figure 7.6:    Global Pharmacogenomics Market (by Sequencing), 2018-2028
Figure 7.7:    Global Pharmacogenomics Market (by Other Technologies), 2018-2028
Figure 8.1:    Global Pharmacogenomics Market (by End User)
Figure 8.2:    Global Pharmacogenomics Market (by End User), 2018 and 2028
Figure 8.3:    Global Pharmacogenomics Market (by Research Organizations), 2018-2028
Figure 8.4:    Research Organizations (by Service), Share 2018 and 2028
Figure 8.5:    Global Pharmacogenomics Market (by Pharmaceutical Companies), 2018-2028
Figure 8.6:    Pharmaceutical Companies (by Service), 2018 and 2028
Figure 8.7:    Global Pharmacogenomics Market (by Diagnostic Centers), 2018-2028
Figure 8.8:    Diagnostics Centers (by Service), 2018 and 2028
Figure 8.9:    Global Pharmacogenomics Market (by Other End Users), 2018-2028
Figure 9.1:    Global Pharmacogenomics Market (by Region), 2018 and 2028
Figure 9.2:    Global Pharmacogenomics Market (by Region), 2018-2028
Figure 9.3:    Global Pharmacogenomics Market Share (by Region), 2018
Figure 9.4:    Global Pharmacogenomics Market Share (by Region), 2028
Figure 9.5:    North America Pharmacogenomics Market, 2018-2028
Figure 9.6:    North America: Market Dynamics
Figure 9.7:    North America Pharmacogenomics Market (by Country), 2018-2028
Figure 9.8:    The U.S. Pharmacogenomics Market, 2018-2028
Figure 9.9:    Canada Pharmacogenomics Market, 2018-2028
Figure 9.10:    North America Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.11:    North America Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.12:    Europe Pharmacogenomics Market, 2018-2028
Figure 9.13:    Europe: Market Dynamics
Figure 9.14:    Europe Pharmacogenomics Market (by Country), 2018-2028
Figure 9.15:    Germany Pharmacogenomics Market, 2018-2028
Figure 9.16:    The U.K. Pharmacogenomics Market, 2018-2028
Figure 9.17:    France Pharmacogenomics Market, 2018-2028
Figure 9.18:    Italy Pharmacogenomics Market, 2018-2028
Figure 9 19:    Spain Pharmacogenomics Market, 2018-2028
Figure 9 20:    Denmark Pharmacogenomics Market, 2018-2028
Figure 9.21:    The Netherlands Pharmacogenomics Market, 2018-2028
Figure 9.22:    Rest-of-Europe Pharmacogenomics Market, 2018-2028
Figure 9.23:    Europe Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.24:    Europe Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.25:    Asia-Pacific Pharmacogenomics Market, 2018-2028
Figure 9.26:    APAC: Market Dynamics
Figure 9.27:    APAC Pharmacogenomics Market (by Country), 2018-2028
Figure 9.28:    Japan Pharmacogenomics Market, 2018-2028
Figure 9.29:    China Pharmacogenomics Market, 2018-2028
Figure 9.30:    Australia Pharmacogenomics Market, 2018-2028
Figure 9.31:    India Pharmacogenomics Market, 2018-2028
Figure 9.32:    Singapore Pharmacogenomics Market, 2018-2028
Figure 9.33:    RoAPAC Pharmacogenomics Market, 2018-2028
Figure 9.34:    Asia-Pacific Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.35:    Asia-Pacific Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.36:    Latin America Pharmacogenomics Market, 2018-2028
Figure 9.37:    Latin America: Market Dynamics
Figure 9.38:    Latin America Pharmacogenomics Market (by Country), 2018-2028
Figure 9.39:    Brazil Pharmacogenomics Market, 2018-2028
Figure 9.40:    Mexico Pharmacogenomics Market, 2018-2028
Figure 9.41:    Rest-of-Latin America Pharmacogenomics Market, 2018-2028
Figure 9.42:    Latin America Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.43:    Latin America Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.44:    RoW Pharmacogenomics Market, 2018-2028
Figure 9.45:    RoW Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.46:    RoW Pharmacogenomics Market (by Service), 2018 and 2028
Figure 10.1:    Total Number of Companies Profiled
Figure 10.2:    Abbott Laboratories: Overall Product Portfolio
Figure 10.3:    Abbott Laboratories: Overall Financials, 2016-2018
Figure 10.4:    Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 10.5:    Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 10.6:    Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 10.7:    Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 10.8:    Abbott Laboratories: SWOT Analysis
Figure 10.9:    Admera Health, LLC: Overall Product Portfolio
Figure 10.10:    Admera Health, LLC: SWOT Analysis
Figure 10.11:    Agena Biosciences, Inc.: Overall Product Portfolio
Figure 10.12:    Agena Biosciences, Inc.: SWOT Analysis
Figure 10.13:    Product Portfolio: Cancer Genetics, Inc.
Figure 10.14:    Cancer Genetics, Inc.: Overall Financials, 2016-2018
Figure 10.15:    Cancer Genetics, Inc.: Revenue (by Segment), 2016-2018
Figure 10.16:    Cancer Genetics, Inc.: R&D Expenditure, 2016-2018
Figure 10.17:    Cancer Genetics, Inc.: SWOT Analysis
Figure 10.18:    Dynamic DNA Laboratories: Overall Product Portfolio
Figure 10.19:    Dynamic DNA Laboratories: SWOT Analysis
Figure 10.20:    F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 10.21:    F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 10.22:    F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
Figure 10.23:    F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
Figure 10.24:    F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
Figure 10.25:    F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 10.26:    F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 10.27:    geneOmbio Technologies Pvt Ltd.: Overall Product Portfolio
Figure 10.28:    geneOmbio Technologies Pvt Ltd.: SWOT Analysis
Figure 10.29:    Genomic Health, Inc.: Overall Product Portfolio
Figure 10.30:    Genomic Health, Inc.: Overall Financials, 2016-2018
Figure 10.31:    Genomic Health, Inc.: Revenue (by Segment), 2016-2018
Figure 10.32:    Genomic Health, Inc.: Revenue (by Region), 2016-2018
Figure 10.33:    Genomic Health, Inc.: R&D Expenditure, 2016-2018
Figure 10.34:    Genomic Health, Inc.: SWOT Analysis
Figure 10.35:    Illumina, Inc.: Overall Product Portfolio
Figure 10.36:    Illumina, Inc.: Overall Financials, 2016-2018
Figure 10.37:    Illumina, Inc.: Revenue (by Segment), 2016-2018
Figure 10.38:    Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 10.39:    Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 10.40:    Illumina, Inc.: SWOT Analysis
Figure 10.41:    Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 10.42:    Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
Figure 10.43:    Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
Figure 10.44:    Laboratory Corporation of America Holdings: Revenue (by Region), 2018
Figure 10.45:    Laboratory Corporation of America Holdings: SWOT Analysis
Figure 10.46:    Myriad Genetics, Inc.: Overall Product Portfolio
Figure 10.47:    Myriad Genetics, Inc.: Overall Financials, 2016-2018
Figure 10.48:    Myriad Genetics, Inc.: Revenue (by Business Segment), 2016-2018
Figure 10.49:    Myriad Genetics, Inc.: SWOT Analysis
Figure 10.50:    Pathway Genomics Corporation: Overall Product Portfolio
Figure 10.51:    Pathway Genomics Corporation: SWOT Analysis
Figure 10.52:    QIAGEN N.V.: Overall Product Portfolio
Figure 10.53:    QIAGEN N.V.: Overall Financials, 2016-2018
Figure 10.54:    QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 10.55:    QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 10.56:    QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 10.57:    QIAGEN N.V.: SWOT Analysis
Figure 10.58:    Product Portfolio: Quest Diagnostics Incorporated
Figure 10.59:    Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 10.60:    Quest Diagnostics Incorporated: Revenue (by Segment), 2016-2018
Figure 10.61:    Quest Diagnostics Incorporated: SWOT Analysis
Figure 10.62:    Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 10.63:    Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 10.64:    Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
Figure 10.65:    Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
Figure 10.66:    Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 10.67:    Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 10.68:    Transgenomic, Inc.: Overall Product Portfolio
Figure 10.69:    Transgenomic, Inc.: SWOT Analysis
Figure 10.70:    23and Me, Inc.: Overall Product Portfolio
Figure 10.71:    OneOme, LLC: Overall Product Portfolio
Figure 11.1:    Global Pharmacogenomics Market Segmentation
Figure 11.2:    Global Pharmacogenomics Market Research Methodology
Figure 11.3:    Primary Research
Figure 11.4:    Secondary Research
Figure 11.5:    Data Triangulation
Figure 11.6:    Bottom-up Approach (Segment-wise Analysis)
Figure 11.7:    Top-down Approach (Segment-wise Analysis)
Figure 11.8:    Assumptions and Limitations
Figure 11.9:    Considered Factors for Data Prediction and Modeling

You may also like

Published Year: 2019

Global Direct-to-Consumer Genetic Testing (DTC-GT) Market: Focus on Direct-to-Consumer Genetic Testi

The global direct-to-consumer market was valued at approximately $824.1 million in 2018 and is...

 
Published Year: 2019

Global Molecular Diagnostics Market: Focus on Product Type (Kits and Consumables, Systems, Software

The global molecular diagnostics market has been witnessing a steady growth since the end of...

 
Published Year: 2018

Global Human Microbiome Modulators Market – Analysis and Forecast, 2018-2023: Focus on Non-Dairy S

The global human microbiome modulators market has been witnessing a steady annual growth rate...

 
Published Year: 2018

Global Non-Invasive Prenatal Testing (NIPT) Market: Focus on Tests, Methods, Platforms, Applications

The global NIPT market is expected to reach $5.67 billion by...

 
Published Year: 2018

Global Liquid Biopsy Market: Focus on Products and Services, Therapeutic Applications, Clinical Appl

The global liquid biopsy market is anticipated to reach $2.94 billion by 2028, witnessing a...

 

Global Pharmacogenomics Market

Focus on Services, Applications, Technologies, End Users, Country Data (16 Countries), and Competitive Landscape – Analysis and Forecast, 2019-2028